In a small human trial in SMA patients neurostimulation sessions improved motoneuron function, reduced fatigue, and improved leg muscle strength and walking.
Zydus Life share rose after it received approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with ALS ...
Study finding Xenon gas could protect against Alzheimer’s disease leads to start of clinical trial
New research from Mass General Brigham and Washington University School of Medicine in St. Louis found Xenon gas inhalation reduced neurodegeneration and boosted protection in preclinical models o ...
Microglia, the brain's primary and most prominent immune ... for treating other diseases such as multiple sclerosis, amyotrophic lateral sclerosis, and eye diseases that involve the loss of ...
Fast forward to 2025: xenon, an odourless noble gas in Group 18 of the periodic table, is now offering hope for Alzheimer’s ...
Microglia, the brain's primary and most prominent immune ... for treating other diseases such as multiple sclerosis, amyotrophic lateral sclerosis, and eye diseases that involve the loss of ...
Microglia, the brain's primary and most prominent immune ... for treating other diseases such as multiple sclerosis, amyotrophic lateral sclerosis, and eye diseases that involve the loss of ...
Collectively, these results suggest that dysregulation of Rho family GTPases may potentially underscore the etiology of some forms of neurodegenerative disease such as amyotrophic lateral sclerosis ..
Microglia, the brain’s primary and most prominent immune cells ... in addition to its potential for treating other diseases such as multiple sclerosis, amyotrophic lateral sclerosis, and eye diseases ...
a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS). Under the leadership of Principal Investigator Prof Merit Cudkowicz, MD, Director of the Sean M. Healey ...
The increasing complexity of the genetic landscape in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia ... with diagnoses of dementia (including behavioural variant FTD, primary ...
Zacks.com on MSN16d
FDA & EMA Accept Biogen's Filings for Higher Dose SMA DrugBiogen BIIB announced that the FDA and EMA have accepted its regulatory filings seeking label expansion for a higher dose of its blockbuster spinal muscular atrophy (SMA) drug Spinraza. This new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback